Roche’s Von Prondzynski Says All is as Planned With FDA and AmpliChip
Last week, when Roche presented it first-half 2003 financial update, Heino von Prondzynski, head of the pharmaceutical giant’s diagnostic division, addressed financial analysts and said that the company will work with the agency to define a standard for analyte specific reagents based on microarray technology.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.